The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 23 March 2004, www.theannals.com, DOI 10.1345/aph.1D283.
 The Annals of Pharmacotherapy: Vol. 38, No. 5, pp. 882-886. DOI 10.1345/aph.1D283
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amabile, C. M
Right arrow Articles by Spencer, A. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amabile, C. M
Right arrow Articles by Spencer, A. P

NEW DRUG DEVELOPMENT

Parecoxib for Parenteral Analgesia in Postsurgical Patients

Celene M Amabile, PharmD

Clinical Pharmacist, Maricopa Integrated Health System, Phoenix, AZ

Anne P Spencer, PharmD BCPS

Associate Professor of Pharmacy Practice, College of Pharmacy, Medical University of South Carolina, Charleston, SC

Reprints: Celene M Amabile PharmD, Maricopa Integrated Health System, 2601 E. Roosevelt St., Phoenix, AZ 85008, fax 602/344-5453, celene.amabile{at}hcs.maricopa.gov

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy and safety studies, adverse effects, drug interactions, and dosage and administration of parecoxib sodium, a selective cyclooxygenase-2 (COX-2) inhibitor.

DATA SOURCES: Information was obtained from MEDLINE searches of the English-language literature (1996–May 2003). Search terms included parecoxib, parecoxib sodium, SC-69124A, and selective cyclooxygenase-2 inhibitor.

STUDY SELECTION AND DATA EXTRACTION: We reviewed available literature, which included abstracts, clinical trials, and data on file with the manufacturer.

DATA SYNTHESIS: Parecoxib sodium is a novel selective COX-2 inhibitor under development for parenteral administration. It has produced efficacious analgesia following dental, gynecologic, and orthopedic surgery. The adverse effect profile has been compared with that of ketorolac; no statistically significant differences were identified. There are no documented drug interactions when parecoxib is coadministered with midazolam, propofol, or unfractionated heparin.

CONCLUSIONS: Parecoxib sodium is in the final stages of Phase III trials and has a favorable safety and efficacy profile. Its place in moderate to severe postsurgical pain management will be further defined when more pharmacoeconomic and postmarketing safety data are available. Theoretical benefits are its lower potential for gastrointestinal adverse effects compared with ketorolac and lower opioid requirements after surgery.

Key Words: parecoxib sodium, SC-69124A

Published Online, March 23, 2004. www.theannals.com, DOI 10.1345/aph.1D283


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
U. Grundmann, C. Wornle, A. Biedler, S. Kreuer, M. Wrobel, and W. Wilhelm
The efficacy of the non-opioid analgesics parecoxib, paracetamol and metamizol for postoperative pain relief after lumbar microdiscectomy.
Anesth. Analg., July 1, 2006; 103(1): 217 - 222.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
R. M. Pertusi
Selective Cyclooxygenase Inhibition in Pain Management
J Am Osteopath Assoc, November 1, 2004; 104(11_suppl): 19S - 24S.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.